Organisation paid for research Program year 2025 Source: CMS Open Payments

Cnrisan Diego LLC

Neither a doctor nor a teaching hospital

Research payments

$1,395,506

48 payments

Through program year 2025, Cnrisan Diego LLC is reported as receiving $1,395,506 in research payments, across 48 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $17,553 7
2024 Research $106,940 6
2023 Research $842,407 15
2022 Research $240,701 5
2021 Research $8,000 1
2020 Research $179,906 14

Breakdown

Who paid Research payments · program years 2020–2025
  1. Sumitomo Pharma America, Inc. $966,900 28 payments
  2. Sunovion Pharmaceuticals Inc. $420,607 19 payments
  3. Neurocrine Biosciences, Inc. $8,000 1 payment
Studies the money was for Research payments · program years 2020–2025
  1. A Randomized Open-Label Single Dose Cross-over Study of Gastric Emptying Rate: SEP-363856 vs Prior Antipsychotic Standard of Care in Subjects with Schizophrenia $461,201 5 payments
  2. An Open-Label Fixed Sequence Multiple Dose Study of Glucose and Insulin Associated Parameters: SEP-363856 vs Prior Antipsychotic (PA) Standard of Care in Subjects with Schizophrenia Suffering from Metabolic Dysregulation $381,206 10 payments
  3. A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia $181,626 3 payments
  4. A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia $158,123 7 payments
  5. A Randomized, Open-Label, Single Dose, Cross-over Study of Gastric Emptying Rate: SEP-363856 vs Prior Antipsychotic Standard of Care in Subjects with Schizophrenia $59,478 3 payments
  6. A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard $59,074 2 payments
  7. An Open-Label, Fixed Sequence, Multiple Dose Study of Glucose and Insulin Associated Parameters: SEP-363856 vs Prior Antipsychotic (PA) Standard of Care in Subjects With Schizophrenia Suffering From Metabolic Dysregulation $47,462 3 payments
  8. A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia $21,783 7 payments
  9. An 8-Week, Open-Label Study Evaluating the Effectiveness, Safety and Tolerability of Sep-363856 in Subjects With Schizophrenia Switched From Typical Or Atypical Antipsychotic Agents $17,553 7 payments
  10. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Subjects With Cognitive Impairment Associated With Schizophrenia, Followed By Open-Label Treatment $8,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record